Report

July 23

Blog: Safety Evaluation of Extractables and Leachables for E-Cigarette Devices

Broughton Nicotine Services announce new webinar.

Safety Evaluation of Extractables and Leachables for E-Cigarette Devices

Broughton Nicotine Services are delighted to announce our new webinar - Safety Evaluation of Extractables and Leachables for E-Cigarette Devices. 

Yvonne Wilding, Director of Product Safety and Compliance provides insight into the regulatory requirements to demonstrate ENDS product safety (e-liquids and vape devices) and explains why evaluation of extractables and leachables needs to be a core component of any product development strategy.

You can listen to the webinar by clicking 'watch now' below:

 

Safety Evaluation of Extractable and Leachables

Have you got a question about the webinar?

Yvonne will be happy to take any questions or comments you may have on the webinar, you can post it here

You may also be interested in our Extractables and Leachables explained brochure:

New call-to-action

 

About the Author

Yvonne Wilding is the Director of Product Safety and Compliance. She has over 10 years of broad regulatory toxicology experience and 20 years of pharmaceutical drug development Research & Development leadership. She has been responsible for numerous MAA and NDA submissions, for both small molecules and biologics and has experience stretching from early candidate selection through life cycle management of new medicines. Her toxicology experience was gained with GlaxoSmithKline's (GSK) large portfolio of respiratory products in a specialized inhalation toxicology department. Yvonne began her career as a regulatory toxicologist for GSK responsible for designing the strategic drug safety evaluation programs to satisfy all global markets using both in-vivo and in-vitro approaches; for operational delivery both with an in-house team and with Contract Research Organisations (CRO). This involved working closely with clinical teams and key opinion leaders to ensure patient safety at each stage of development. She has extensive experience of interacting with regulatory agencies. Following on from Toxicology, Yvonne was responsible for managing and leading drug development programs encompassing all functional disciplines to ensure delivery of successful marketing applications and to maximise the commercial opportunity for each product. Yvonne’s clinical experience encompasses clinical program strategy, study management, clinical portfolio management and pharmacovigilance. Most recently, Yvonne worked with AstraZeneca in the Precision Medicine department to develop new diagnostic tests and submit PMA applications for companion diagnostics devices evaluating genetic biomarkers of disease susceptibility in collaboration with major diagnostic companies.